How Private Equity Rescued a Critical OR Drug from the Brink

BRIDGEWATER, NJ – November 10, 2026 – In the meticulously controlled ecosystem of a hospital operating room, there are few scenarios more terrifying than a patient suddenly developing malignant hyperthermia. This rare, life-threatening hypermetabolic crisis, often triggered by routine anesthesia, turns the body into a runaway furnace. Muscles go rigid, heart rates skyrocket, and internal temperatures climb to lethal levels within minutes. For anesthesiologists and surgical teams, the margin between life and death is razor-thin. The only reliable biological circuit breaker for this physiological catastrophic event is a rapid intravenous infusion of dantrolene sodium.

For years, the gold standard in this emergency response has been RYANODEX, an innovative formulation of dantrolene sodium that drastically reduces the time required to mix and administer the life-saving antidote. However, behind the sterile walls of the surgical suite lies a complex and often fragile global supply chain. When the corporate entity responsible for manufacturing a critical rescue medication begins to fracture financially, the tremors are felt by hospital procurement officers worldwide. Today, that uncertainty has been definitively quelled. Cosette Pharmaceuticals, a rapidly expanding specialty pharmaceutical company, announced that it has successfully completed the supply chain transition for RYANODEX following its June 2026 acquisition of the drug. The medication is now fully stocked and available across both United States and international markets, securing a vital node in the global medical supply network.

Safeguarding the Operating Room: The Mechanics of a Rescue Drug

To understand the strategic importance of this supply chain stabilization, one must look at the clinical reality of malignant hyperthermia. Before the FDA approval of RYANODEX in 2014, treating a patient experiencing this crisis required medical staff to rapidly reconstitute dozens of individual vials of older dantrolene formulations with sterile water—a frantic, labor-intensive process that consumed precious minutes. RYANODEX revolutionized this protocol through a proprietary nanosuspension technology, allowing a therapeutic dose to be prepared and administered from a single vial in less than a minute.

Because of this clinical advantage, the drug became an indispensable fixture in surgical centers and hospital pharmacies. Regulatory guidelines and standard-of-care protocols effectively mandate that facilities performing general anesthesia stockpile dantrolene sodium. Consequently, the drug is not just a pharmaceutical product; it is a mandatory insurance policy for the modern operating room.

Yet, the indispensability of a resource often highlights the vulnerability of its supply. When the sole manufacturer of a critical node in emergency care faces headwinds, the entire medical infrastructure is forced to brace for impact. Hospital risk managers and pharmacy directors are acutely aware of the FDA Drug Shortages Database, an ever-updating ledger of systemic failures in the pharmaceutical supply chain. Ensuring that a critical care formulation never appears on that list is a matter of paramount domestic health security.

The Financial Fault Lines of Eagle Pharmaceuticals

The vulnerability in the RYANODEX supply chain originated not in the laboratory, but in the boardroom of its previous owner, Eagle Pharmaceuticals. Over the past two years, the former parent company navigated a perilous financial landscape that ultimately forced the divestiture of its most critical assets. By 2024, the enterprise was grappling with severe operational challenges, including delayed Securities and Exchange Commission filings and the daunting requirement to restate financial statements dating back to mid-2022.

The financial instability reached a critical juncture when trading in the company's common stock was suspended on the Nasdaq in late 2024, relegating it to the OTC Expert Market. For hospital procurement networks, a supplier pushed to the financial brink is a massive red flag. The capital required to maintain stringent manufacturing compliance, source raw active pharmaceutical ingredients, and manage complex sterile injectable distribution networks is immense. An organization struggling to maintain its market listing is often one that may soon struggle to maintain its manufacturing output.

The dismantling of the portfolio began in earnest in early 2026. In January, the struggling firm divested the acute care drug Barhemsys to streamline operations and generate desperately needed cash for ongoing business operations. It was a clear signal to the market that non-core and even essential assets were being liquidated for survival. By June 2026, the rights to RYANODEX were quietly acquired by Cosette Pharmaceuticals, transferring the stewardship of this essential emergency drug to a much more stable financial platform.

Private Equity and Critical Niche Assets: The Acquisition Strategy

The rescue of RYANODEX is a textbook example of a broader, hidden current in the global economy: the role of private equity in stabilizing critical infrastructure. Cosette is not a traditional pharmaceutical behemoth; it is a highly agile specialty firm backed by heavy-hitting private equity sponsors, specifically Avista Healthcare Partners and Hamilton Lane.

In July 2024, Hamilton Lane acquired a significant equity interest in the Bridgewater-based company, joining Avista in joint control. This injection of private markets capital was explicitly designed to optimize the balance sheet, accelerate research and development, and, crucially, fund strategic acquisitions. The private equity model in specialty pharma often involves identifying distressed or non-core assets trapped within larger or struggling companies, extracting them, and applying rigorous operational discipline to maximize their value and ensure supply reliability.

The firm has aggressively executed this playbook. Over recent years, it has absorbed a string of well-known brands, acquiring products from Sanofi US, Daiichi Sankyo, and Assertio Holdings. By integrating these orphaned or divested drugs into its robust manufacturing and distribution network, the specialty pharmaceutical company acts as a stabilizing force in the broader healthcare market.

"Our acquisition of RYANODEX reflects Cosette's commitment to expanding access to important medicines and ensuring the infrastructure is in place to support them," noted Apurva Saraf, President and Chief Executive Officer of Cosette Pharmaceuticals, in the official announcement. "Our ability to successfully integrate RYANODEX and ensure a dependable supply demonstrates the strength of our organization and our focus on delivering for healthcare providers and patients."

Engineering Supply Chain Resilience

Acquiring the intellectual property and marketing rights to a drug is only the first step; physically transferring the manufacturing of a complex injectable suspension is a formidable engineering and regulatory challenge. Sterile injectables require exacting environmental controls, rigorous quality assurance, and flawless supply chain redundancies to prevent contamination and ensure efficacy.

The announcement that the supply chain transition is complete and the product is fully stocked serves as a critical proof of concept for the acquiring firm's operational capabilities. Operating significant manufacturing facilities in New Jersey and North Carolina, the company boasts a long history of handling complex dosage forms. Their recent success in navigating the FDA approval process for their own New Drug Application, EVOXAC, further underscores their regulatory competence. By leveraging these established domestic manufacturing hubs, they mitigate the geopolitical and logistical risks that often plague overseas pharmaceutical production.

For the medical professionals standing at the operating table, the corporate maneuvering that secures their tools is largely invisible, but its impact is absolute. "Healthcare providers depend on having the medicines they need, when they need them," stated Brad Leonard, Vice President of Commercial Operations at Cosette Pharmaceuticals. "Our priority is to ensure hospitals and healthcare providers have dependable access to RYANODEX, so they can focus on what matters most: delivering timely care to patients."

The successful transition of this life-saving formulation from a distressed asset to a fully stabilized, readily available medical resource highlights a vital mechanism in modern healthcare. It demonstrates how targeted private capital and specialized manufacturing expertise can intersect to rescue critical technologies from financial turbulence, ensuring that when the worst-case scenario unfolds in the surgical suite, the necessary cure is waiting in the pharmacy.